Teleflex (NYSE:TFX) Reaches New 52-Week High – Here’s What Happened

Teleflex Incorporated (NYSE:TFX)’s share price reached a new 52-week high on Wednesday. The company traded as high as $147.99 and last traded at $144.9860, with a volume of 20,802 shares changing hands. The stock had previously closed at $139.95.

Wall Street Analysts Forecast Growth

TFX has been the subject of a number of analyst reports. Weiss Ratings reiterated a “sell (d)” rating on shares of Teleflex in a report on Monday, September 21st. UBS Group upped their target price on shares of Teleflex from $145.00 to $158.00 and gave the stock a “neutral” rating in a report on Tuesday, August 11th. Wall Street Zen raised shares of Teleflex from a “sell” rating to a “hold” rating in a research report on Sunday, August 9th. Needham & Company LLC raised their price target on shares of Teleflex from $159.00 to $170.00 and gave the company a “buy” rating in a research report on Tuesday, August 25th. Finally, Bank of America upgraded Teleflex from a “neutral” rating to a “buy” rating and lifted their price target for the company from $145.00 to $158.00 in a research note on Monday, September 28th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, five have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Teleflex presently has a consensus rating of “Moderate Buy” and a consensus price target of $154.40.

Teleflex Stock Up 4.6%

The stock has a fifty day moving average of $131.43 and a 200 day moving average of $125.37. The company has a debt-to-equity ratio of 0.94, a current ratio of 2.60 and a quick ratio of 2.12. The firm has a market capitalization of $6.20 billion, a P/E ratio of -6.27, a price-to-earnings-growth ratio of 0.94 and a beta of 0.85.

Teleflex (NYSE:TFX) last announced its quarterly earnings data on Thursday, August 6th. The medical technology company reported $1.76 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.28 by $0.48. Teleflex had a positive return on equity of 11.93% and a negative net margin of 39.67%. The firm had revenue of $570.33 million during the quarter, compared to the consensus estimate of $559.59 million. During the same quarter in the prior year, the company earned $3.73 EPS. The business’s revenue for the quarter was up 28.9% on a year-over-year basis. Teleflex has set its FY 2026 guidance at 6.900-7.200 EPS. On average, research analysts anticipate that Teleflex Incorporated will post 7.22 EPS for the current fiscal year.

Hedge Funds Weigh In On Teleflex

Several institutional investors have recently added to or reduced their stakes in the stock. GAMMA Investing LLC increased its holdings in Teleflex by 9.8% during the third quarter. GAMMA Investing LLC now owns 921 shares of the medical technology company’s stock worth $115,000 after buying an additional 82 shares during the last quarter. Hsbc Holdings PLC raised its position in Teleflex by 4.7% in the first quarter. Hsbc Holdings PLC now owns 1,861 shares of the medical technology company’s stock worth $222,000 after acquiring an additional 84 shares during the period. Baldwin Wealth Partners LLC MA boosted its stake in Teleflex by 7.5% in the third quarter. Baldwin Wealth Partners LLC MA now owns 1,702 shares of the medical technology company’s stock valued at $213,000 after acquiring an additional 119 shares during the last quarter. Leonteq Securities AG boosted its stake in Teleflex by 13.6% in the first quarter. Leonteq Securities AG now owns 1,164 shares of the medical technology company’s stock valued at $139,000 after acquiring an additional 139 shares during the last quarter. Finally, Sage Rhino Capital LLC boosted its stake in Teleflex by 9.5% in the first quarter. Sage Rhino Capital LLC now owns 1,837 shares of the medical technology company’s stock valued at $220,000 after acquiring an additional 159 shares during the last quarter. Institutional investors own 95.62% of the company’s stock.

Teleflex Company Profile

Teleflex Incorporated is a global medical technology company that develops, manufactures and markets specialty medical devices. Its products are designed to support healthcare professionals in critical care and procedural settings, including vascular access, interventional cardiology and radiology, anesthesia, respiratory care, emergency medicine, surgical applications and urology.

The company’s portfolio includes catheters, access and closure devices, airway-management products, surgical instruments, pain-management devices and other technologies used in hospitals and outpatient facilities.